• Prescribing Information
  • Medical Information
  • Dosing and Coadministration

    TRUMENBA offers a 2-dose option for adolescent and young adult patients.1

    Card CTA

    ** This is an optional area where footnotes can live.


    • If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose1 

    Advisory Committee on Immunization Practices (ACIP) recommends the 2-dose schedule when given to healthy adolescents and young adults aged 16 through 23 years who are not at increased risk for meningococcal disease, based on shared clinical decision-making.2,3
    ​​​​​​​
    ​​​​​​​On average, young adults return to the doctor after 6 to 8 months.4†

    Enroll in the REMEMBER TRUMENBA program

    2-dose series
    ​​​​​​​Text "TRU2" to the number 37500

    Card CTA
    Card CTA

    ** This is an optional area where footnotes can live.

    ACIP recommends the 3-dose schedule for persons aged ≥10 years, who are in a MenB outbreak situation or at increased risk for meningococcal disease. 

    These persons include those with persistent complement component deficiencies, those with anatomic or functional asplenia, or microbiologists routinely exposed to isolates of Neisseria meningitidis.​​​​​​​

    Enroll in the REMEMBER TRUMENBA program

    3-dose series
    ​​​​​​​Text "TRU3" to the number 37500

    Card CTA

       *The choice of dosing schedule may depend on the risk of exposure and the patient’s susceptibility to meningococcal serogroup B disease.1

       Data collected in March 2017 from a survey of 593 young adults (aged 16-21 years) and/or patients/caregivers across the United States.

       Including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab (Soliris®; Alexion Pharmaceuticals, Inc.)

    Only TRUMENBA has been studied with other adolescent vaccines1,3


    • Concomitant administration did not significantly increase local reactions or systemic events compared with TRUMENBA alone5,6

    The immunogenicity of concomitantly administered TRUMENBA with HPV4, MCV4, and Tdap vaccines was evaluated in adolescents.1​​​​​​​

    • The noninferiority criteria were met for all immunogenicity endpoints for MenB strains, MCV4, and Tdap antigens, as well as for HPV antigens, with the exception of HPV-181
    • Seroconversion for all 4 HPV antigens was achieved by ≥99% of subjects in the groups that received HPV4 (secondary endpoint)5
    Data are not available to assess the safety and immunogenicity of concomitant administration of TRUMENBA with other routine adolescent vaccines.1​​​​​​

       ¶HPV4=quadrivalent human papillomavirus vaccine; HPV=human papillomavirus; MCV4=quadrivalent meningococcal conjugate vaccine; MenB=serogroup B meningococcal disease; Tdap=tetanus, diphtheria, and pertussis vaccine.​​​​​​​​​​​​​​​​​​​​​​​​​​​​

    Contact your Pfizer Representative or call a Vaccine Specialist at 
    1-844-439-2571.


    References:
    1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.
    2. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2020. Centers for Disease Control and Prevention website. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed July 6, 2020.
    3. MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1176.
    4. QuintilesIMS primary market research study, 2017.
    5. Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Disease J. 2016;35(5):548-554.
    6. Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability, and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673-682.
    7. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed July 6, 2020.
    8. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450.
    9. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9.
    10. Ewald AJ, McKeag DB. Meningitis in the athlete. Curr Sports Med Rep. 2008;7(1):22-27.

    Pfizer TruSupport

    • Ordering options​​​​​​​
    • Patient coverage confirmation
    • Essential tools
    • Resources for your practice
    Find out about TruSupport

    Why adolescents and young adults?

    Typical adolescent and young adult behaviors increase MenB risk.4,6-8​​​​

    Learn about MenB

    The science behind TRUMENBA

    Only TRUMENBA targets both subfamilies, A and B, of fHBP.1

    See the science

    Indication

    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
    • Severe allergic reaction after a previous dose of Trumenba is a contraindication
    • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
    • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
    • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
    • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
    • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
    • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
    • Safety and effectiveness have not been established in pregnant women
    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

    Please see full Prescribing Information.​​​​​​​